Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection

Liliana Elena Weimer; Vincenzo Fragola; Marco Floridia; Giovanni Guaraldi; Nicoletta Ladisa; Daniela Francisci; Rita Bellagamba; Anna Degli Antoni; Giustino Parruti; Andrea Giacometti; Paolo Emilio Manconi; Angela Vivarelli; Gabriella D'Ettorre; Maria Stella Mura; Stefania Cicalini; Roberta Preziosi; Laura Sighinolfi; Gabriella Verucchi; Raffaella Libertone; Marcello Tavio; Loredana Sarmati; Raffaella Bucciardini; G. Angarano; A. Volpe; V. Vullo; G. Ceccarelli; M. Andreoni; D. Delle Rose; V. Tozzi; P. Narciso; N. Petrosillo; V. Pucillo; C. Tommasi; D. Segala; O. Armignacco; C. Ferrari; A. Cavalli; F. Sozio; L. Cosentino; F. Ortu; P. Viale; S. Tedeschi; R. Manfredi; M. Mannazzu; G. Cattari; R. Del Gobbo; A. Mataloni Paggi; O. Cirioni; E. Marchionni; C. Silvestri; L. Brescini; S. Sebastianelli; F. Baldelli; A. Mercuri; S. Bastianelli; G. Nardini; M. Massella; S. Baroncelli; C. M. Galluzzo; M. F. Pirillo; M. G. Mancini; R. Amici; A. Cara; R. Bona; P. Leone; P. Filati; M. Franco; S. Donnini

doi:10.1093/jac/dks341

Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection

Liliana Elena Weimer, Vincenzo Fragola, Marco Floridia, Giovanni Guaraldi, Nicoletta Ladisa, Daniela Francisci, Rita Bellagamba, Anna Degli Antoni, Giustino Parruti, Andrea Giacometti, Paolo Emilio Manconi, Angela Vivarelli, Gabriella D'Ettorre, Maria Stella Mura, Stefania Cicalini, Roberta Preziosi, Laura Sighinolfi, Gabriella Verucchi, Raffaella Libertone, Marcello TavioLoredana Sarmati, Raffaella Bucciardini, G. Angarano, A. Volpe, V. Vullo, G. Ceccarelli, M. Andreoni, D. Delle Rose, V. Tozzi, P. Narciso, N. Petrosillo, V. Pucillo, C. Tommasi, D. Segala, O. Armignacco, C. Ferrari, A. Cavalli, F. Sozio, L. Cosentino, F. Ortu, P. Viale, S. Tedeschi, R. Manfredi, M. Mannazzu, G. Cattari, R. Del Gobbo, A. Mataloni Paggi, O. Cirioni, E. Marchionni, C. Silvestri, L. Brescini, S. Sebastianelli, F. Baldelli, A. Mercuri, S. Bastianelli, G. Nardini, M. Massella, S. Baroncelli, C. M. Galluzzo, M. F. Pirillo, M. G. Mancini, R. Amici, A. Cara, R. Bona, P. Leone, P. Filati, M. Franco, S. Donnini

Research output: Contribution to journal › Article › peer-review

Abstract

Objectives: To define the impact of coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) on viroimmunological response to raltegravir-based salvage regimens that also include new HIV inhibitors such as maraviroc, darunavir and etravirine. Methods: We used data from a national observational study of patients starting raltegravir-based regimens to compare virological suppression and CD4 cell change from baseline in patients with and without concomitant HBV or HCV infection. Results: Overall, 275 patients (107 coinfected and 168 non-coinfected) were evaluated. Coinfected patients were more commonly former intravenous drug users and had a longer history of HIV infection and higher baseline aminotransferase levels. Both HIV-RNA and CD4 response were similar in the two groups. Mean time to first HIV-RNA copy number

Original language	English
Pages (from-to)	193-199
Number of pages	7
Journal	Journal of Antimicrobial Chemotherapy
Volume	68
Issue number	1
DOIs	https://doi.org/10.1093/jac/dks341
Publication status	Published - Jan 2013

Keywords

Antiretroviral therapy
CD4 response
Darunavir
Etravirine
HBV
HCV
HIV resistance
HIV-1
Integrase inhibitors
Liver disease
Maraviroc
Viral hepatitis
Viral load

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1093/jac/dks341

Cite this

Weimer, L. E., Fragola, V., Floridia, M., Guaraldi, G., Ladisa, N., Francisci, D., Bellagamba, R., Degli Antoni, A., Parruti, G., Giacometti, A., Manconi, P. E., Vivarelli, A., D'Ettorre, G., Mura, M. S., Cicalini, S., Preziosi, R., Sighinolfi, L., Verucchi, G., Libertone, R., ... Donnini, S. (2013). Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. Journal of Antimicrobial Chemotherapy, 68(1), 193-199. https://doi.org/10.1093/jac/dks341

Weimer, LE, Fragola, V, Floridia, M, Guaraldi, G, Ladisa, N, Francisci, D, Bellagamba, R, Degli Antoni, A, Parruti, G, Giacometti, A, Manconi, PE, Vivarelli, A, D'Ettorre, G, Mura, MS, Cicalini, S, Preziosi, R, Sighinolfi, L, Verucchi, G, Libertone, R, Tavio, M, Sarmati, L, Bucciardini, R, Angarano, G, Volpe, A, Vullo, V, Ceccarelli, G, Andreoni, M, Delle Rose, D, Tozzi, V, Narciso, P, Petrosillo, N, Pucillo, V, Tommasi, C, Segala, D, Armignacco, O, Ferrari, C, Cavalli, A, Sozio, F, Cosentino, L, Ortu, F, Viale, P, Tedeschi, S, Manfredi, R, Mannazzu, M, Cattari, G, Del Gobbo, R, Mataloni Paggi, A, Cirioni, O, Marchionni, E, Silvestri, C, Brescini, L, Sebastianelli, S, Baldelli, F, Mercuri, A, Bastianelli, S, Nardini, G, Massella, M, Baroncelli, S, Galluzzo, CM, Pirillo, MF, Mancini, MG, Amici, R, Cara, A, Bona, R, Leone, P, Filati, P, Franco, M & Donnini, S 2013, 'Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection', Journal of Antimicrobial Chemotherapy, vol. 68, no. 1, pp. 193-199. https://doi.org/10.1093/jac/dks341

@article{a30ff63ad9844d2cb452ad9cf2e291d5,

title = "Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection",

abstract = "Objectives: To define the impact of coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) on viroimmunological response to raltegravir-based salvage regimens that also include new HIV inhibitors such as maraviroc, darunavir and etravirine. Methods: We used data from a national observational study of patients starting raltegravir-based regimens to compare virological suppression and CD4 cell change from baseline in patients with and without concomitant HBV or HCV infection. Results: Overall, 275 patients (107 coinfected and 168 non-coinfected) were evaluated. Coinfected patients were more commonly former intravenous drug users and had a longer history of HIV infection and higher baseline aminotransferase levels. Both HIV-RNA and CD4 response were similar in the two groups. Mean time to first HIV-RNA copy number ",

keywords = "Antiretroviral therapy, CD4 response, Darunavir, Etravirine, HBV, HCV, HIV resistance, HIV-1, Integrase inhibitors, Liver disease, Maraviroc, Viral hepatitis, Viral load",

author = "Weimer, {Liliana Elena} and Vincenzo Fragola and Marco Floridia and Giovanni Guaraldi and Nicoletta Ladisa and Daniela Francisci and Rita Bellagamba and {Degli Antoni}, Anna and Giustino Parruti and Andrea Giacometti and Manconi, {Paolo Emilio} and Angela Vivarelli and Gabriella D'Ettorre and Mura, {Maria Stella} and Stefania Cicalini and Roberta Preziosi and Laura Sighinolfi and Gabriella Verucchi and Raffaella Libertone and Marcello Tavio and Loredana Sarmati and Raffaella Bucciardini and G. Angarano and A. Volpe and V. Vullo and G. Ceccarelli and M. Andreoni and {Delle Rose}, D. and V. Tozzi and P. Narciso and N. Petrosillo and V. Pucillo and C. Tommasi and D. Segala and O. Armignacco and C. Ferrari and A. Cavalli and F. Sozio and L. Cosentino and F. Ortu and P. Viale and S. Tedeschi and R. Manfredi and M. Mannazzu and G. Cattari and {Del Gobbo}, R. and {Mataloni Paggi}, A. and O. Cirioni and E. Marchionni and C. Silvestri and L. Brescini and S. Sebastianelli and F. Baldelli and A. Mercuri and S. Bastianelli and G. Nardini and M. Massella and S. Baroncelli and Galluzzo, {C. M.} and Pirillo, {M. F.} and Mancini, {M. G.} and R. Amici and A. Cara and R. Bona and P. Leone and P. Filati and M. Franco and S. Donnini",

year = "2013",

month = jan,

doi = "10.1093/jac/dks341",

language = "English",

volume = "68",

pages = "193--199",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection

AU - Weimer, Liliana Elena

AU - Fragola, Vincenzo

AU - Floridia, Marco

AU - Guaraldi, Giovanni

AU - Ladisa, Nicoletta

AU - Francisci, Daniela

AU - Bellagamba, Rita

AU - Degli Antoni, Anna

AU - Parruti, Giustino

AU - Giacometti, Andrea

AU - Manconi, Paolo Emilio

AU - Vivarelli, Angela

AU - D'Ettorre, Gabriella

AU - Mura, Maria Stella

AU - Cicalini, Stefania

AU - Preziosi, Roberta

AU - Sighinolfi, Laura

AU - Verucchi, Gabriella

AU - Libertone, Raffaella

AU - Tavio, Marcello

AU - Sarmati, Loredana

AU - Bucciardini, Raffaella

AU - Angarano, G.

AU - Volpe, A.

AU - Vullo, V.

AU - Ceccarelli, G.

AU - Andreoni, M.

AU - Delle Rose, D.

AU - Tozzi, V.

AU - Narciso, P.

AU - Petrosillo, N.

AU - Pucillo, V.

AU - Tommasi, C.

AU - Segala, D.

AU - Armignacco, O.

AU - Ferrari, C.

AU - Cavalli, A.

AU - Sozio, F.

AU - Cosentino, L.

AU - Ortu, F.

AU - Viale, P.

AU - Tedeschi, S.

AU - Manfredi, R.

AU - Mannazzu, M.

AU - Cattari, G.

AU - Del Gobbo, R.

AU - Mataloni Paggi, A.

AU - Cirioni, O.

AU - Marchionni, E.

AU - Silvestri, C.

AU - Brescini, L.

AU - Sebastianelli, S.

AU - Baldelli, F.

AU - Mercuri, A.

AU - Bastianelli, S.

AU - Nardini, G.

AU - Massella, M.

AU - Baroncelli, S.

AU - Galluzzo, C. M.

AU - Pirillo, M. F.

AU - Mancini, M. G.

AU - Amici, R.

AU - Cara, A.

AU - Bona, R.

AU - Leone, P.

AU - Filati, P.

AU - Franco, M.

AU - Donnini, S.

PY - 2013/1

Y1 - 2013/1

N2 - Objectives: To define the impact of coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) on viroimmunological response to raltegravir-based salvage regimens that also include new HIV inhibitors such as maraviroc, darunavir and etravirine. Methods: We used data from a national observational study of patients starting raltegravir-based regimens to compare virological suppression and CD4 cell change from baseline in patients with and without concomitant HBV or HCV infection. Results: Overall, 275 patients (107 coinfected and 168 non-coinfected) were evaluated. Coinfected patients were more commonly former intravenous drug users and had a longer history of HIV infection and higher baseline aminotransferase levels. Both HIV-RNA and CD4 response were similar in the two groups. Mean time to first HIV-RNA copy number

AB - Objectives: To define the impact of coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) on viroimmunological response to raltegravir-based salvage regimens that also include new HIV inhibitors such as maraviroc, darunavir and etravirine. Methods: We used data from a national observational study of patients starting raltegravir-based regimens to compare virological suppression and CD4 cell change from baseline in patients with and without concomitant HBV or HCV infection. Results: Overall, 275 patients (107 coinfected and 168 non-coinfected) were evaluated. Coinfected patients were more commonly former intravenous drug users and had a longer history of HIV infection and higher baseline aminotransferase levels. Both HIV-RNA and CD4 response were similar in the two groups. Mean time to first HIV-RNA copy number

KW - Antiretroviral therapy

KW - CD4 response

KW - Darunavir

KW - Etravirine

KW - HBV

KW - HCV

KW - HIV resistance

KW - HIV-1

KW - Integrase inhibitors

KW - Liver disease

KW - Maraviroc

KW - Viral hepatitis

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=84871242042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871242042&partnerID=8YFLogxK

U2 - 10.1093/jac/dks341

DO - 10.1093/jac/dks341

M3 - Article

C2 - 22984206

AN - SCOPUS:84871242042

VL - 68

SP - 193

EP - 199

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 1

ER -

Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this